Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers.
de Bono, J
Dean, Emma J
AffiliationDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1901 East Road, Houston, TX, 77054, USA
MetadataShow full item record
AbstractProviral integration Moloney virus (PIM) kinases (PIM1, 2 and 3) are overexpressed in several tumour types and contribute to oncogenesis. AZD1208 is a potent ATP-competitive PIM kinase inhibitor investigated in patients with recurrent or refractory acute myeloid leukaemia (AML) or advanced solid tumours.
CitationPhase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. 2018, Br J Cancer
JournalBritish Journal of Cancer